J
John Ramage
Researcher at Hampshire Hospitals NHS Foundation Trust
Publications - 165
Citations - 8428
John Ramage is an academic researcher from Hampshire Hospitals NHS Foundation Trust. The author has contributed to research in topics: Neuroendocrine tumors & Medicine. The author has an hindex of 39, co-authored 144 publications receiving 6773 citations. Previous affiliations of John Ramage include National Health Service & HealthPartners.
Papers
More filters
Journal ArticleDOI
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
John Ramage,A Ahmed,J Ardill,N.D.S. Bax,David J. Breen,Martyn Caplin,Pippa Corrie,J Davar,Albert Davies,Val Lewington,Tim Meyer,John Newell-Price,Graeme J. Poston,N. Reed,Andrea Rockall,William P. Steward,Rajesh V. Thakker,C. Toubanakis,Juan W. Valle,Caroline S. Verbeke,Ashley B. Grossman +20 more
TL;DR: These guidelines update previous guidance published in 2005 and have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour Society with endorsement from the clinical committees of the British Society of Gastroenterology and others.
Journal ArticleDOI
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
Martyn Caplin,Eric Baudin,Piero Ferolla,P.L. Filosso,Mariano García-Yuste,Eric Lim,Kjell Öberg,Giuseppe Pelosi,Aurel Perren,Roberta Elisa Rossi,Roberta Elisa Rossi,William D. Travis,Detlief Bartsch,Jaume Capdevila,Frederico Costa,Jarosław B. Ćwikła,Wouter W. de Herder,Gianfranco Delle Fave,Barbro Eriksson,Massimo Falconi,Diego Ferone,David J. Gross,Ashley B. Grossman,Tetsuhide Ito,Robert T. Jensen,Gregory Kaltsas,Fahrettin Kelestimur,Reza Kianmanesh,Ulrich Knigge,Beata Kos-Kudła,Eric P. Krenning,Emmanuel Mitry,Marianne Nicolson,Juan Manuel O'Connor,Dermot O'Toole,Ulrich Frank Pape,Marianne Pavel,John Ramage,Eric Raymond,Guido Rindi,Andrea Rockall,Philippe Ruszniewski,Ramon Salazar,Aldo Scarpa,Eva Sedlackova,Anders Sundin,Christos Toumpanakis,Marie Pierre Vullierme,Wolfgang Weber,Bertram Wiedenmann,Zeng Zheng-Pei +50 more
TL;DR: PCs are complex tumors which require a multidisciplinary approach and long-term follow-up, and may be considered as first-line systemic antiproliferative treatment in unresectable PCs, particularly of low-grade TC and AC.
Journal ArticleDOI
ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms.
G. Delle Fave,Dermot O'Toole,Anders Sundin,B. G. Taal,Piero Ferolla,John Ramage,Diego Ferone,Tetsuhide Ito,W. Weber,Z. Zheng-Pei,W. W. de Herder,Andreas Pascher,Philippe Ruszniewski +12 more
TL;DR: a Department of Digestive and Liver Disease, Ospedale Sant’Andrea, Rome , Italy; b NET Centre, St Vincent’s University and Department of Clinical Medicine, St. James Hospital and Trinity College, Dublin , Ireland;
Journal ArticleDOI
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.
Angela Lamarca,Daniel H. Palmer,Harpreet Wasan,Paul Ross,Yuk Ting Ma,Arvind Arora,Stephen Falk,Roopinder Gillmore,Jonathan Wadsley,Kinnari Patel,Alan Anthoney,Anthony Maraveyas,Timothy Iveson,Justin S. Waters,Claire Hobbs,Safia Barber,W David J Ryder,John Ramage,Linda Davies,John Bridgewater,Juan W. Valle +20 more
TL;DR: The ABC-06 clinical trial was a phase 3, open-label, randomised trial done in 20 sites with expertise in managing biliary tract cancer across the UK.
Journal ArticleDOI
Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease
Julie Parkes,Paul Roderick,Scott Harris,Christopher P. Day,David Mutimer,Jane Collier,Martin Lombard,Graeme J.M. Alexander,John Ramage,Geoffrey Dusheiko,Mark Wheatley,Carol Gough,Alastair D. Burt,William Rosenberg +13 more
TL;DR: Survival analysis showed that the ELF score predicts liver outcomes, with people having the highest ELF scores being significantly more likely to have clinical outcomes than those in lower-score groups.